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Summary
Background: Obeticholic acid (OCA) was recently approved as the only on-label al-
ternative for patients with primary biliary cholangitis (PBC) with intolerance or sub-
optimal response to ursodeoxycholic acid (UDCA). However, few data are available 
outside clinical trials.
Aim: To assess the effectiveness and safety of OCA in a real-world cohort of patients 
with non-effective UDCA therapy.
Methods: Open-label, prospective, real-world, multicentre study, enrolling consec-
utive patients who did not meet Paris II criteria, from 18 institutions in Spain and 
Portugal. Effectiveness was assessed by the changes in GLOBE and UK-PBC scores 
from baseline. POISE and Paris II criteria were evaluated after 12 months of OCA. 
Liver fibrosis was evaluated by FIB-4 and AST to platelet ratio index (APRI).
Results: One hundred and twenty patients were eligible, median time since PBC 
diagnosis 9.3 (4.0-13.8) years, 21.7% had cirrhosis, and 26.7% received had previ-
ous or concomitant treatment with fibrates. Seventy-eight patients completed at 
least 1 year of OCA. The Globe-PBC score decreased to 0.17 (95% CI 0.05 to 0.28; 
P = 0.005) and the UK-PBC score decreased to 0.81 (95% CI −0.19 to 1.80; P = 0.11). 
There was a significant decrease in alkaline phosphatase of 81.3 U/L (95% CI 42.5 to 
120; P < 0.001), ALT 22.1 U/L (95% CI 10.4 to 33.8; P < 0.001) and bilirubin 0.12 mg/
dL (95% CI 0 to 0.24; P = 0.044). FIB-4 and APRI remained stable. According to the 
POISE criteria, 29.5% (23 out of 78) achieved response. The adverse events rate was 
35%; 11.67% discontinued (8.3% due to pruritus).
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1  | INTRODUC TION
Traditionally, primary biliary cholangitis (PBC) has been considered 
a rare disease with an important lack of therapeutic options. This 
chronic, usually slow-progressive, cholestatic liver disease is char-
acterised by the immune-mediated destruction of interlobular bile 
ducts, thus leading to cholestasis, portal inflammation, fibrosis and, 
with time and insufficient response to therapy, end-stage liver dis-
ease.1,2 Whereas histologic features help in the disease staging, the 
key parameters for diagnosis, according to current consensus guide-
lines, are the co-existence of elevated cholestatic serum biomarkers 
(serum alkaline phosphatase [AP], gamma-glutamyl-transpeptidase [γ-
GT] and bilirubin) and specific anti-mitochondrial antibodies.3 Liver bi-
opsy is not required for confirming PBC diagnosis, yet this procedure 
may be needed for AMA-negative and overlap syndromes. Transient 
elastography (TE) has been increasingly replacing liver biopsy for fi-
brosis staging. However, this non-invasive procedure has not been 
extensively validated in PBC as in other chronic liver diseases.4 In re-
cent years, in order to improve risk stratification, several tools, based 
on biochemical markers and response to first-line ursodeoxycholic 
acid (UDCA) therapy5,6 have been designed and validated to allow 
the clinical prediction of risk. Moreover, other non-invasive surrogate 
biomarkers of fibrosis, already validated for other liver diseases, have 
been extensively used in PBC as prognostic markers.7,8
The early identification and close management of patients with 
PBC, especially now that new therapeutic options are available for 
those who showed a suboptimal response to UDCA. Fibrates have 
shown an important impact on AP and bilirubin levels, though no 
benefit in terms of reversal of fibrosis and/or inflammation has been 
shown; their use is still off-label for PBC disease, as some safety 
concerns, specifically its impact on liver transaminases levels still 
remain.9 OCA was approved in 2017 in Europe for the therapeutic 
management of patients with PBC as a second line agent.10 OCA 
acts directly on the farnesoid X receptor, showing both in pre-clini-
cal and clinical data a pleiotropic effect on cholestasis, inflammation 
and liver fibrosis.10-14 Outside the clinical trial setting, there are very 
few reports assessing its effectiveness and tolerability in real clini-
cal practice.15 The aim of this study was to assess the effectiveness 
and safety of OCA on a real-world patient scenario, of unselected 
non-responder patients to 12-month UDCA therapy (Paris II criteria).
2  | METHODS
2.1 | Patients and study design
The IBER Leading study group is a scientific consortium of 18 hos-
pitals from Spain and Portugal that has designed this open-label, 
real practice, prospective study to assess OCA effectiveness and 
safety among adult patients diagnosed with PBC with a subopti-
mal response or intolerance to UDCA or disease progression to ad-
vanced fibrosis despite adequate biochemical response. Response 
to OCA was assessed by the continuous prognostic scoring systems 
GLOBE and UK-PBC.5,10,16 In addition, dichotomous scores POISE 
and Paris II criteria were used to evaluate OCA response after at 
least 12 months of full dose UDCA therapy (13-15 mg/kg/day).3,17 
Eligibility criteria were no response to the Paris II criteria to UDCA 
or UDCA plus fibrates therapy after at least 1 year of UDCA treat-
ment or the presence of advanced liver fibrosis (F4) even when these 
patients met the Paris II criteria at baseline. However, the latter did 
not enter the final analysis (Figure 1).
Patients with overlap syndrome PBC-autoimmune hepatitis as 
the criteria of Zhang et al18 were also eligible.
Most enrolled patients (65%) were followed-up for at least 
12 months once OCA therapy was initiated. Blood samples were 
drawn every three months in order to assess the evolution of bio-
chemical, cholestatic and inflammation markers. Patients were 
categorised in subgroups according to the presence of an optimal 
response to OCA therapy at the end of the first year of follow-up.
Cirrhosis was diagnosed by liver biopsy (n = 13), TE 
value ≥ 16.9 kPa (n = 5), and by ultrasound (Nodular liver surface 
plus splenomegaly or increased diameter of portal vein or ascites or 
thrombocytopenia <100 × 109 platelets) and clinical and biological 
signs of cirrhosis (n = 8).
Conclusions: This study supports data from phase III trials with significant improve-
ment of PBC-Globe continuous prognostic marker score among OCA-treated patients 
with good tolerability.
F I G U R E  1   Flow chart of patients
Non-Responders to UDCA or
to UDCA+Fibrates (n = 32)
n = 125
OCA (n = 117)
At least 12 months of F-U with
OCA treatment (n = 78) 
• N = 5 (Whithin Paris II 
criteria, but with
advanced liver fibrosis)
• N = 3 Transplanted
• N = 2 (Lost to F-U)
Eligible OCA (n = 115)
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Thirty two patients had received fibrates prior to OCA initiation, 
of these, fibrates were discontinued in ten patients, five due to in-
effectiveness and five due to toxicity (four due to increased amino-
transferases and one due to worsening of mild renal dysfunction). 
Two more patients received fibrates after OCA initiation. Therefore, 
twenty four patients continued receiving fibrates after OCA initiation.
The study was conducted after informed consent according to 
the principles of the Declaration of Helsinki and approved by the 
Institutional Research Board of the corresponding centre, and at 
each participating centre, in accordance with local regulations.
2.2 | End-points
The primary end-point of the study was the effect on the con-
tinuous GLOBE and UK-PBC prognostic scores.5,16 Secondary 
end-points were the rate of response according to POISE criteria 
(AP ≤ 1.67 × ULN, with a reduction of at least 15% from base-
line, and bilirubin ≤1 mg/dL),10 the rate of response according 
to Paris II criteria (ALP ≤ 1.5 × ULN and AST ≤ 1.5 × ULN and 
bilirubin ≤ 1 mg/dL),17 the biochemical response to OCA therapy, 
measured as changes on AP, bilirubin, alanine (ALT) and aspartate 
aminotransferases (AST), the changes on surrogate markers of fi-
brosis, such as FIB-4 and AST to platelet ratio index (APRI), after 
12 months of therapy and the third end-point was to assess toler-
ability and safety of the therapy.
2.3 | Clinical parameters
Baseline demographic, clinical, biochemical, histopathological and 
elastographic parameters were collected for recruited patients, in-
cluding age, sex, time since PBC diagnosis and UDCA initiation, se-
ropositivity to AMA and ANA antibodies, pruritus or liver fibrosis 
stage. Baseline was defined as the date OCA therapy was initiated. 
Each patient enrolled in the study was monitored every 3 months for 
AP, γ-GT. bilirubin, ALT, AST, total cholesterol, platelets, prothrom-
bin INR, albumin and triglycerides. Additionally, IgM and IgG levels 
were monitored as surrogate markers of inflammation. Liver fibrosis 
was also monitored every 3 months by FIB-4 and the APRI param-
eters, and a liver TE performed by TE (Echosens FibroScan 502) was 
performed when available at baseline and month 12.
Pruritus was assessed by verbal rating scale, 1 is mild pruritus, 2 
moderate and 3 severe, this scale has shown good correlation with 
visual analogue scales.19
2.4 | Statistical analyses
Results were expressed as median and interquartile range for continu-
ous variables and counts and percentages for categorical variables. To 
observe the effect of treatment on the parameters throughout time, 
linear mixed models and generalised linear mixed models for repeated 
measures were used.17 The time effect was included as repeated 
measure and adjusted by age. An unstructured variance matrix was 
considered. The estimated mean differences and 95% confidence in-
tervals (95% CI) are presented. To analyse time effect by response, 
an interaction effect time × response was added to mixed models. 
Pairwise comparisons were adjusted using Bonferroni method.
To identify potential predictive factors associated with Paris II 
optimal response at 12 months, a univariate analysis was performed 
using the chi-squared test or Fisher's exact test for qualitative vari-
ables, and the Mann-Whitney U test for quantitative variables. 
The variables associated were introduced in multivariate modified 
Poisson regression model20,21 to predict Paris II optimal response 
at 12 months. Receiver operating characteristic (ROC AUC) curves 
were constructed to evaluate the predictive capacity of parameters 
and multivariate model linear predictor. The differences were con-
sidered statistically significant for P < 0.05. The statistical analyses 
were performed using SPSS software (v. 19.0).
3  | RESULTS
3.1 | Patients characteristics
A total of 125 patients were recruited and 120 of them were eli-
gible. Figure 1 shows the patients’ flow chart recruited from 18 
Spanish and Portuguese Medical Centres involved in the study, 
whose baseline characteristics are shown in Table 1. As shown, most 
patients were female (97%), with a median age of 55.9 (48.2-63) 
years. Median time since PBC diagnosis was 9.3 (4-13.8) years. Up 
to 21.7% of the patients enrolled in the study showed cirrhosis at 
baseline, while 26.7% had received fibrates before the initiation of 
OCA therapy and 20% received fibrates in combination with UDCA 
and OCA. Up to 10% of the patients showed an overlap PBC/autoim-
mune hepatitis syndrome.
There were five patients with advanced fibrosis who met the 
Paris II criteria at baseline (n = 5), in these patients the median 
ULNx values of AP was 1.27 (0.94-1.4); Bilirubin 0.61 (0.55-0.8); 
ALT 1.06 (0.83-1.37) and AST (ULNx) 1.09 (0.9-1.34). At baseline, 
five patients met Paris II but not Poise criteria. Conversely, there 
were 14 patients with optimal response to POISE but suboptimal 
to Paris II Criteria. The criteria for eligibility were lack of response 
to Paris II criteria after at least 1 year of treatment with UDCA or 
UDCA plus fibrates.
In 23 AMA-negative patients, diagnosis was confirmed by liver 
biopsy in 21 cases, the remaining two patients had intrahepatic 
cholestasis, increased serum IgM and positivity for Anti-GP-210.
3.2 | Continuous Prognostics scores of PBC and 
surrogate markers of liver fibrosis
UK-PBC decreased to 0.81 (CI95%: −0.19 to 1.8) at 12 months 
from baseline (P = 0.11). The GLOBE score showed significant 
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improvements up to 0.165 (CI 95%: 0.05-0.28) (P = 0.005) (Table 2 
and Figure 2).
3.3 | Biochemical changes in markers of 
cholestasis and inflammation after 12 months of 
OCA therapy
Seventy-eight patients completed at least 1 year of treatment 
with OCA. Overall, the biochemical markers assessed along the 
study period showed statistically significant decrease compared 
to baseline. The estimated means decrease at 12 months was 
81.32 U/L (CI95%: 42.5-120) in AP, 22.1 U/L (CI95%: 10.44-33.77) 
in ALT, 13.9 (CI95%: 5.34-22.48) in AST and 0.12 (CI95%:0-0.24) 
in bilirubin (Table 2 and Figure 3). No significant changes were 
found in IgG levels, however, IgM showed a significant decrease 
from month 3 after OCA initiation 72.19 mg/dL less at 12 months 
(CI95%: 28.6-115.77) (Table 2). Total cholesterol decreased to 
22.5 mg/dL (CI95%: 8.25-36.78) after 12 months of treatment 
with OCA (Table 2).
3.4 | Fibrosis evolution with OCA therapy
The surrogate markers of liver fibrosis FIB-4 and APRI did not 
change throughout the 12 months of OCA treatment. TE results 
showed that patients experimented a stabilisation of their liver fi-
brosis throughout this period (Table 2).
3.5 | Factors associated to POISE and Paris II 
criteria response
Patients treated with OCA were evaluated at the end of the 
12 months of follow-up based on both POISE and Paris II criteria. 
According to the POISE criteria 23 out of 78 patients achieved 
response (29.5%). The only factor associated to POISE response 
was serum albumin levels of 4.5 (4.2-4.6) vs 4.2 (4-4.4) (P = 0.003; 
Table 3). Paris II criteria response were achieved by 15 out 78 
patients (19.2%). Lower levels of AP (215.0 [198.0-280.0] U/L 
vs 287 [214.8-402] U/L, P = 0.005), total bilirubin (0.5 [0.5-0.8] 
mg/dL vs 0.8 [0.6-1.1] mg/dL, P = 0.008) and triglycerides (123.0 
[98.8-191.8] mg/dL vs 88.0 [67-132] mg/dL, P = 0.012) at baseline 
were associated with good response to OCA therapy. These three 
factors remained independently associated to response at multi-
variate analysis (Table 4). Serum levels of triglycerides were not 
correlated with age or the stage of liver fibrosis. A multivariate 
model was constructed, the ROC AUC for AP, Bilirubin and tri-
glycerides was 0.753, 0.719 and 0.744 respectively, showing good 
predictive accuracy for Paris II response, the multivariate model 
linear predictor showed the best ROC AUC 0.877 (CI 95%: 0.79-
0.967, Figure S1).
TA B L E  1   Baseline demographic, clinical and biochemical 
characteristics of the eligible patients
N = 120
Age, years (median, IQR) 55.9 (48.2-63.1)
Time since diagnosis, years (median, IQR) 9.3 (4-13.8)
Females (n, %) 116 (96.7)
AMA+ (n, %) 97 (80.8)
ANA + (n, %) 65 (54.2)
Cirrhosis (n, %) 26 (21.7)
CPT A5-A6 (n, %) 20 (80)
CPT B7-B8 (n, %) 5 (20)
Oesophageal varices (n, %) 13 (10.8)
Other autoimmune diseases (n, %) 25 (20.8)
Previous fibrates therapy (n, %) 32 (26.7)
Concomitant fibrates (n, %) 24 (20)
Overlap syndrome (n, %) 12 (10)
Liver biopsy (n, %) 77 (64.2)
Baseline OCA dosage, years (median, IQR) 5 (5-5)
Alkaline phosphatase, U/L (median, IQR) 244 (204-361)
Alkaline Phosphatase × ULN (median, IQR) 2.1 (1.8-2.9)
ALT, U/L (median, IQR) 47 (31-74)
ALT × ULN (median, IQR) 1.4 (0.9-2.1)
AST, U/L (median, IQR) 44 (33-64)
AST × ULN (median, IQR) 1.4 (1-2)
Bilirubin, mg/dL (median, IQR) 0.7 (0.5-1.1)
Bilirubin × ULN (median, IQR) 0.6 (0.5-0.9)
Platelet count, ×109 cells/µL (median, IQR) 228.5 (164-300.8)
Platelet count × LLN (median, IQR) 1.4 (0.8-2)
INR (median, IQR) 1 (0.9-1)
Albumin, g/dL (median, IQR) 4.2 (4-4.4)
Albumin × LLN (Median, IQR) 1.2 (1.1-1.3)
IgG, mg/dL (median, IQR) 1315.5 
(1142.5-1549.8)
IgM, mg/dL (median, IQR) 335 (226-452)
Cholesterol, mg/dL (median, IQR) 225 (196-260)
Triglycerides, mg/dL (median, IQR) 91 (68-125)
Transient elastography, kPa (median, IQR) 7.9 (6.5-11.3)
MELD (median, IQR) 6 (6-7)
GLOBE-score (median, IQR) 0.3 (−0.4 to 0.9)
PBC globe risk 3 y (median, IQR) 1 (0.9-1)
PBC globe risk 5 y (Median, IQR) 0.9 (0.8-1)
PBC globe risk 10y (median, IQR) 0.8 (0.6-0.9)
PBC globe risk 15y (median, IQR) 0.7 (0.5-0.8)
APRI (median, IQR) 0.6 (0.4-1)
FIB-4 (median, IQR) 1.6 (1.1-2.5)
UK PBC 5y (median, IQR) 2.1 (1.1-3.9)
UK PBC 10y (median, IQR) 6.9 (3.7-12.6)
UK PBC 15y (median, IQR) 12.5 (6.8-22.2)
Follow-up months (median, IQR) 12.3 (6.9-16.9)
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Baseline 116 <0.001b 308.45 16.06
3 104 252.84 14.58 55.611* 25.94 85.28
6 99 252.65 14.26 55.804* 24.49 87.12
12 78 227.13 12.52 81.325* 42.53 120.12
ALT (U/L) Baseline 116 <0.001b 59.53 4.19
3 104 46.70 2.94 12.834* 4.83 20.84
6 100 40.82 2.83 18.709* 7.02 30.40
12 78 37.43 2.44 22.104* 10.44 33.77
AST (U/L) Baseline 116 <0.001b 52.24 3.32
3 104 43.10 2.26 9.141* 2.75 15.53
6 100 38.88 1.77 13.364* 4.89 21.83
12 78 38.33 1.69 13.912* 5.34 22.48
TB (mg/dL) Baseline 115 0.044a 0.88 0.06
3 104 0.79 0.05 0.095* 0.00 0.19
6 100 0.78 0.04 0.10 −0.02 0.23
12 78 0.77 0.05 0.12 −0.01 0.24
IgG (mg/dL) Baseline 83 0.643 1384.42 38.87
3 34 1363.02 48.78 21.40 −79.28 122.08
6 31 1341.13 38.46 43.29 −51.62 138.20
12 28 1355.65 38.87 28.78 −56.09 113.65
IgM (mg) Baseline 81 0.001a 383.39 25.86
3 35 326.77 22.94 56.626* 13.43 99.82
6 31 318.35 22.31 65.043* 24.64 105.44
12 29 311.20 25.51 72.188* 28.60 115.77
Platelet count (×109) Baseline 115 <0.001b 235.44 8.28
3 101 223.87 8.38 11.569* 3.00 20.14
6 98 222.30 8.33 13.140* 2.10 24.18
12 76 218.31 8.92 17.134* 5.22 29.05
INR Baseline 111 0.137 1.02 0.03
3 90 1.02 0.02 0.00 −0.02 0.02
6 88 1.03 0.03 −0.01 −0.03 0.02
12 74 1.04 0.03 −0.02 −0.04 0.01
Albumin (g/dL) Baseline 111 0.631 4.22 0.03
3 90 4.20 0.03 0.02 −0.04 0.09
6 88 4.19 0.04 0.03 −0.05 0.11
12 74 4.21 0.04 0.01 −0.07 0.08
Cholesterol (mg/dL) Baseline 102 0.001b 234.34 5.54
3 83 219.27 4.62 15.066* 3.37 26.76
6 84 217.21 5.17 17.126* 3.44 30.81
12 68 211.82 4.96 22.517* 8.25 36.78
Triglycerides (mg/dL) Baseline 102 0.301 109.20 6.02
3 81 102.26 4.75 6.95 −5.67 19.56
(Continues)
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A significant decrease was observed in AP, ALT, AST and bilirubin 
with OCA treatment in the whole cohort. However, the mixed model 
detects different trend time in POISE responders vs. non-responders 
regarding alkaline phosphatase decrease. By contrast, no significant 
interaction effect time-response was observed in both groups re-












6 82 105.20 5.32 4.00 −7.50 15.49
12 64 99.05 4.61 10.15 −4.45 24.74
Transient 
elastography (kPa)
Baseline 85 0.491 13.31 1.35
12 39 13.71 1.49 −0.40 −1.56 0.77
MELD Baseline 92 0.800 6.72 0.14
3 77 6.66 0.13 0.06 −0.16 0.28
6 73 6.70 0.17 0.02 −0.26 0.30
12 63 6.76 0.18 −0.04 −0.42 0.34
APRI Baseline 115 0.424 0.84 0.07
3 101 0.81 0.08 0.04 −0.10 0.17
6 98 0.76 0.09 0.09 −0.10 0.28
12 76 0.76 0.08 0.09 −0.07 0.24
FIB4 Baseline 115 0.235 2.16 0.15
3 101 2.21 0.16 −0.05 −0.32 0.21
6 98 2.23 0.20 −0.07 −0.49 0.34
12 76 2.34 0.17 −0.18 −0.41 0.05
PBC-GLOBE Baseline 111 0.005b 0.31 0.07
12 73 0.14 0.08 0.165* 0.05 0.28
UK-PBC5y Baseline 111 0.110 3.76 0.55
12 73 2.95 0.53 0.81 −0.19 1.80
*P < 0.05. 
aP < 0.01.
bP < 0.01.
TA B L E  2   (Continued)
F I G U R E  2   OCA effect on continuous outcome scores Globe-PBC and UK-PBC. Mixed models estimated means with standard error bars 
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3.6 | Tolerability and safety of OCA therapy
In this study cohort, 35% of the patients showed an episode of ad-
verse event, particularly pruritus (32%). However, 30 patients (24%), 
experienced grade 1 pruritus at baseline. Eight patients developed liver 
decompensation during OCA therapy, three of them discontinued and 
underwent liver transplantation. Ten more cases (8.3%) discontinued 
due to grade 2-3 pruritus and one more case discontinued due to a flare 
of cytolysis, this patient had an overlap syndrome PBC-AIH (Table 5).
Pharmacological management of pruritus included cholestyr-
amine (69%), antihistamines (11.9%), bezafibrate (7.1%), naltrexone 
(4.8%), sertraline (2.4%) and topical calamine oinment, hydratant 
creams and pramoxine cream (4.8%). In addition, there was a reduc-
tion of OCA doses in all cases before definitive withdrawal.
OCA dose was up-titrated to 10 mg in 31 patients, 12 at 6 months 
and 19 at 12 months.
Seven patients suffered decompensation during OCA treatment, 
five developed ascites, two patients suffered rupture of oesophageal 
varices, one of them secondary to pre-sinusoidal portal hyperten-
sion associated to nodular regenerative hyperplasia. Three of the 
patients with ascites underwent liver transplantation. OCA was 
withdrawn in three patients with ascites, in one patient with overlap 
PBC/autoimmune hepatitis OCA due to a flare of cytolysis and in 
10 cases due to persistent grade 2-3 pruritus (8.3%). Therefore, 14 
patients discontinued OCA treatment (11.67%)
In decompensated patients who continued receiving OCA, dos-
age was adjusted up to 10 mg twice a week in one patient. However, 
dosage was adjusted up to 5 mg three times a week in four cases of 
tolerance concerns with a dose of 10 mg twice a week.
4  | DISCUSSION
One third of patients with PBC are non-responders to UDCA and 
the survival rate in these patients is lower than in the age-and sex-
matched healthy population.22 The management of PBC disease 
F I G U R E  3   Effect of OCA on liver inflammatory and cholestatic serum markers. Mixed models estimated means with standard errors bars 
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TA B L E  3   Univariate analysis of patients with optimal vs suboptimal response to OCA therapy according to POISE and Paris-II criteria
POISE response POISE No response
P-value
PARISII Optimal PARISII Suboptimal
P-value
n = 23, 29.5% n = 55 n = 15, 19.2% n = 63
CI95%: 
20.5%-40.4% CI 95%:12%-29.3%
Gender Female 23 55 15 63
Cirrhosis No 19 (30.2%) 44 (69.8%) 1 13 (20.6%) 50 (79.4%) 0.722
Yes 4 (26.7%) 11 (73.3%) 2 (13.3%) 13 (86.7%)
Cirrhosis No cirrhosis 19 (30.2%) 44 (69.8%) 0.771 13 (20.6%) 50 (79.4%) 1
CPT A5-6 4 (33.3%) 8 (66.7%) 2 (16.7%) 10 (83.3%)
CPT B7-9 3 (100%) 3 (100%)
Other autoinmune 
diseases
No 18 (30.5%) 41 (69.5%) 0.727 10 (16.9%) 49 (83.1%) 0.503
Yes 5 (26.3%) 14 (73.7%) 5 (26.3%) 14 (73.7%)
Fibrates No 15 (26.3%) 42 (73.7%) 0.312 13 (22.8%) 44 (77.2%) 0.331
Yes 8 (38.1%) 13 (61.9%) 2 (9.5%) 19 (90.5%)
Concomitant fibrates 
therapy
No 17 (27.9%) 44 (72.1%) 0.56 13 (21.3%) 48 (78.7%) 0.501
Yes 6 (35.3%) 11 (64.7%) 2 (11.8%) 15 (88.2%)
Concomitant 
treatment
No 13 (33.3%) 26 (66.7%) 0.456 9 (23.1%) 30 (76.9%) 0.389
Yes 10 (25.6%) 29 (74.4%) 6 (15.4%) 33 (84.6%)
Overlap No 19 (27.1%) 51 (72.9%) 0.225 13 (18.6%) 57 (81.4%) 0.646
Yes 4 (50%) 4 (50%) 2 (25%) 6 (75%)
Age at OCA therapy 
start
Median (IQR) 53.2 (46.4-61.4) 57.1 (49.9-64.5) 0.343 59.8 (51.4-62.6) 54.4 (44.9-63.5) 0.358
Years from diagnosis Median (IQR) 10.9 (5.7-13.8) 11.4 (6.1-14.8) 0.713 11.7 (8.9-18.2) 11 (5.6-14.4) 0.425
Mean doses at 
baseline
Median (IQR) 5 (5-5) 5 (5-5) 0.15 5 (5-5) 5 (5-5) 0.733
Uptitrated to target 
dose of 10 mg
No 12 (30.8%) 27 (69.2%) 0.894 8 (20.5%) 31 (79.5%) 0.834
Yes 10 (32.3%) 21 (67.7%) 7 (22.6%) 24 (77.4%)
Alkaline phosphatase 
(U/L)
Median (IQR) 242 (208-303) 279 (209-388) 0.357 215 (198-280) 287 (214-402) 0.005a
Alkaline 
Phosphatase × ULN
Median (IQR) 2.1 (1.9-2.8) 2.4 (2-3.6) 0.308 1.9 (1.6-2.3) 2.4 (2-3.6) 0.003a
ALT (U/L) Median (IQR) 52 (31-74) 42 (27-74) 0.408 52 (29-69) 43 (28-77) 0.944
ALT × ULN Median (IQR) 1.6 (0.9-2.2) 1.2 (0.8-2.1) 0.417 1.6 (0.9-2) 1.2 (0.8-2.2) 0.834
AST (U/L) Median (IQR) 36 (31-60) 44 (32-65) 0.580 33 (31-53) 45 (31-71) 0.097
AST × ULN Median (IQR) 1.1 (0.9-2) 1.4 (0.9-2) 0.788 1.1 (0.9-1.6) 1.4 (0.9-2.2) 0.101
Bilirubin (mg/dL) Median (IQR) 0.7 (0.5-1) 0.8 (0.5-1.1) 0.449 0.5 (0.5-0.8) 0.8 (0.6-1.1) 0.008a
Bilirubin × ULN Median (IQR) 0.6 (0.5-0.8) 0.7 (0.5-1) 0.463 0.5 (0.4-0.7) 0.7 (0.5-1) 0.008a
Bilirubin (mg/dL) <2 22 (31.9%) 47 (68.1%) 0.268 15 (21.7%) 54 (78.3%) 0.193
>2 1 (11.1%) 8 (88.9%) 9 (100%)
Platelet count (×109/L) Median (IQR) 274 (192-337) 224 (165-311) 0.164 255 (168-285) 231 (183-319) 0.478
Platelet count × LLN Median (IQR) 1.8 (1.1-2.4) 1.4 (0.8-2.1) 0.245 1.7 (0.8-1.9) 1.5 (1-2.1) 0.474
INR Median (IQR) 1 (1-1) 1 (0.9-1) 0.071 1 (0.9-1) 1 (0.9-1) 0.463
Albumin (g/dL) Median (IQR) 4.5 (4.2-4.6) 4.2 (4-4.4) 0.003a 4.3 (4.1-4.6) 4.2 (4-4.5) 0.407
Albumin × LLN Median (IQR) 1.3 (1.2-1.3) 1.2 (1.1-1.3) 0.005a 1.2 (1.2-1.3) 1.2 (1.1-1.3) 0.266
IgG (mg/dL) Median (IQR) 1337 (1140-1803) 1280 (1150-1470) 0.514 1290 (1018.5-1823) 1311 (1145-1516.5) 0.992
IgM (mg/dL) Median (IQR) 345.5 (247.5-505) 356 (275-478.5) 0.660 380.5 (234.5-775.5) 356 (261.8-464.3) 0.589
Cholesterol (mg/dL) Median (IQR) 220 (201-243) 234.5 (195.3-269.8) 0.467 209 (192.8-232.5) 235 (201-277) 0.096
(Continues)
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has recently evolved with the development of tools to stratify 
patients based on risk, and the possibility to treat with second 
line therapy.23 Recent studies suggest that clinical biochemical 
parameters together with non-invasive measures of fibrosis can 
efficiently identify the stage and predict outcomes.5,24-26 These 
observations highlight the key importance of monitoring these pa-
tients, to identify the stage of the disease on an individual basis, 
especially now that new therapeutic strategies have emerged.10 
Our results confirm a significant improvement of continuous prog-
nostic risk score GLOBE-PBC, however the improvement in UK-
PBC did not reach significance, these results may be due to a 
relatively low number of patients reaching 1 year of follow-up.16 
There was an improvement of liver biochemical parameters, over-
all these results in the real-world setting confirm those observed 
in the POISE trial.10 While substantial data exist from clinical tri-
als, very scarce information on real-life treatment with OCA is 
available.15 The response rate according to the POISE criteria was 
slightly lower than those observed in the trial.10 There are sev-
eral explanations for these results. First, the study population is a 
priori a hard-to-treat population, not only because of the relatively 
high percentage of cirrhotic patients (22%) similar to that included 
in the POISE trial,10 but also because these are patients who had 
suboptimal response to UDCA for a long time. In addition, ap-
proximately 26.7% of the patients have received OCA as a third 
line therapy, since they were previously treated with both UDCA 
plus fibrates. Additionally, over 25% of the patients enrolled in the 
study were younger than 50 years, which has been associated to 
worse disease prognosis.27-29 In addition, OCA therapy may have 
significant benefit in POISE non-responders as the biochemical 
inflammatory and bilirubin reduction in POISE non-responders, 
showed a similar time-trend to POISE responders.
Unlike UDCA or fibrates, OCA has demonstrated choleretic and 
antifibrotic effects through a putative mechanism of action targeting 
POISE response POISE No response
P-value
PARISII Optimal PARISII Suboptimal
P-value
n = 23, 29.5% n = 55 n = 15, 19.2% n = 63
CI95%: 
20.5%-40.4% CI 95%:12%-29.3%
Triglycerides (mg/Dl) Median (IQR) 99 (67-136) 88 (70.3-137.5) 0.840 123 (98.8-191.8) 88 (67-132) 0.012a
Transient elastography 
(kPa)
Median (IQR) 8.6 (6.4-10.9) 8.8 (6.3-14.1) 0.684 8.7 (6.6-10.8) 8.6 (6.4-14.2) 0.897
MELD Median (IQR) 6 (6-6.3) 6 (6-7) 0.221 6 (6-6) 6 (6-7) 0.111
GLOBE Median (IQR) 0 (−0.4 to 0.4) 0.4 (−0.3 to 1.4) 0.041a -0.1 (−0.6 to 0.5) 0.3 (−0.3-1.2) 0.103
APRI Median (IQR) 0.6 (0.4-0.7) 0.6 (0.4-1.2) 0.324 0.6 (0.3-0.7) 0.6 (0.4-1.1) 0.329
FIB-4 Median (IQR) 1.2 (0.9-1.8) 1.5 (1.1-2.5) 0.089 1.4 (1.1-1.7) 1.4 (1-2.5) 0.790
UK PBC 5y Median (IQR) 1.7 (1.2-2.4) 2.4 (1.2-5) 0.152 1.5 (0.8-2.2) 2.2 (1.3-4.8) 0.013a
aP < 0.01.
bP < 0.01.
TA B L E  3   (Continued)
TA B L E  4   Multivariate modified Poisson regression model. 
Besides to the three factors found associated to a Paris II response, 
we introduced age as a recognized factor of response that could 
also be related to increased triglyceride levels
Incidence 
rate ratio P-value 95%CI
Baseline AP/10 (U/L) 0.914 0.003a 0.862 0.970
Baseline BT/0.1 (mg/dL) 0.885 0.011a 0.806 0.972
Baseline triglicerydes/10 
(mg/dL)
1.083 0.008a 1.021 1.150
Age OCA start 0.996 0.891 0.935 1.060
aP < 0.01.
bP < 0.01.





Adverse events (n, %) 42 (35) 6 (23.1)
Serious adverse event (2 with 
transplantation) (n, %)
8 (7) 3 (11.5)
Discontinuation OCA pruritus (n, %) 10 (8.3) 1 (3.8)
Discontinuation (Cytolytic flare in 
overlap syndrome PBC-AIH)
1 (0.83)
Discontinuation due to decompensation 
(n, %)
3 (2.5) 3 (11.55)
Total discontinuation 14 (11.67) 4 (15.4)
Pruritus (n, %) (30 patients experienced 
pruritus at baseline)
38 (31.7) 5 (19.2)
Other (n, %) 6 (5) 1 (3.8)
Fatigue (n, %) 4 (3.3) 1 (3.8)
Headache (n, %) 2 (1.7)
Nausea (n, %) 1 (0.8)
Nasopharyngitis (n, %) 1 (0.8)
Arthralgia (n, %) 1 (0.8)
Decompensation during OCA (n, %) 8 (6.7) 5 (19.2)
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the Farneosoid X receptor (FXR). This target is also able to regulate 
immune response and inflammation, two key counterparts in PBC.30 
Our results point towards these beneficial effects with a reduction 
in inflammation and immune-modulatory markers, such as IgM, and 
stabilisation of the stage of fibrosis.
Of note, both PBC-Globe continuous prognostic score signifi-
cantly improved after 1 year of OCA therapy, this score trans-
lates clinical and biochemical parameters into transplant-free 
survival.5,16
We speculated that the platelet count decline could be due 
to an anti-inflammatory effect of OCA. This decrease has been 
previously described in patients with cirrhosis,15 the authors 
claimed a note of caution with OCA dose in these patients. 
However, we did not see any difference in the platelet count re-
duction with cirrhosis (P = 0.364) or with age ≥ 60 or <60 years 
old (P = 0.672). In any case, the decline was small and clinically 
not relevant. This platelet count reduction may have prevented 
a significant decrease in APRI and FIB-4 scores as the platelet 
count is part of the denominator of these surrogate markers of 
liver fibrosis.
The higher levels of serum albumin were associated to higher re-
sponse rate to POISE criteria, it may reflect that treatment initiation 
in early stages of liver disease increases the likelihood of response 
to OCA therapy.31
The lower rate of Paris II response in patients with lower levels 
of triglycerides was not associated with younger age or with higher 
stages of liver fibrosis. We speculate that low fasting triglyceride 
levels may be associated to higher stages of liver fibrosis. In this re-
gard, a recent large American population-based study has showed 
an inverse relationship between liver fibrosis indicators and fasting 
serum triglycerides.32
Regarding the tolerability and safety of the OCA therapy in this 
cohort, it is worthy to note that pruritus remains the main adverse 
event, though a great proportion of the patients already had it at 
baseline, and only nine patients experienced pruritus on a de novo 
basis after the initiation of OCA. This relatively low rate of patients 
experiencing pruritus with OCA may be related with the high pro-
portion of patients with the dose of 5 mg.13 Although the exact 
mechanism of this cholestatic pruritus remains to be elucidated, two 
hypotheses have arisen: the activation of the autotaxin pathway33 or 
the activation of TGR5,34,35 another target of OCA.36 Paradoxically, 
OCA activation of TGR5 improves ethanol-induced liver injury in 
murine models.37
In conclusion, we present this observational study of real-world 
clinical practice assessing the efficacy and tolerability of OCA in a 
hard-to-treat cohort of patients with PBC. Most patients benefitted 
from the treatment with OCA in terms of improvement of Globe-
PBC scoring system, and about one third achieved the POISE cri-
teria at the end of the first 12 months of therapy, considering the 
hard-to-treat profile of patients enrolled in the study. In addition, 
those who did not achieve these criteria showed significant improve-
ments of some biochemical parameters. Further studies and longer 
follow-up would be needed to identify whether this population 
can be considered as slow responders instead of non-responders. 
Moreover, an improvement in immunomodulatory markers and sta-
bilisation of fibrosis progression was noted. Finally, OCA did not in-
duce unexpected adverse events.
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